Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus.
Endocr Connect
; 11(11)2022 Nov 01.
Article
en En
| MEDLINE
| ID: mdl-36228658
'What's in a name? That which we call a rose/By any other name would smell as sweet' (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word, and it therefore represents a convention with no intrinsic meaning. While this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rationale for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology, and pediatric endocrine societies now proposes changing the name of 'diabetes insipidus' to 'arginine vasopressin deficiency (AVP-D)' for central etiologies, and 'arginine vasopressin resistance (AVP-R)' for nephrogenic etiologies. This article provides both the historical context and the rationale for this proposed name change.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Endocr Connect
Año:
2022
Tipo del documento:
Article
País de afiliación:
Japón